The Human Variable 

Journals, mobile apps, and wearable devices can capture delayed reactions, multi-system flares, partial recovery cycles, and gradual changes in baseline function. These features are central to autoimmune and IACC biology, but are rarely visible in single-visit care. This guide explains how symptom journaling works in the context of immune-mediated illness.

IACC Twin™ is a CYNAERA framework that integrates two capabilities into one model: Longitudinal flare forecasting that detects short-term risk windows and identifies the dominant drivers of volatility (environment, sleep, delayed response timing, and intervention confounding). Phase-style therapy sequencing that models safe “one-change-per-window” layering, including stop and revert logic, to reduce avoidable crashes and improve signal interpretability in fragile patients.

Infection-associated chronic conditions (IACCs), including Long COVID, ME/CFS, post-treatment Lyme disease syndrome (PTLDS), and related post-infectious syndromes, present a persistent challenge to conventional medical workflows. These conditions are multi-system, fluctuating, and temporally delayed, with symptom expression shaped by environmental exposures, autonomic regulation, immune reactivity, hormonal state, and cumulative demand.

Here I apply CYNAERA’s analytical framework to the unlikely case of a consumer snack, Frito-Lay’s Baked Lay’s, as an emergent functional-nutrition platform for dysautonomia and MCAS patients. Using CYNAERA’s prevalence modeling (US-CCUC™, S³™, Pathos™, SymCas™, BRAGS™) and global market-behavior analytics, I examine how a legacy brand could reposition a common product into a precision-nutrition solution. A $3 billion opportunity in plain sight.

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.

This white paper argues that MCS and MCAS are vantage points on a shared hypersensitivity terrain, proposing a new classification, Multi-Chemical and Environmental Hypersensitivity Disorders (MCEHD), that unites them, honors patient ingenuity, and formalizes my frameworks.